Citizen – Follow up
A group of researchers has identified 3 drugs that have already been approved as potential treatments for COVID-19, the disease caused by SARS-CoV-2.
The discovery is the product of work by researchers at the University of Tennessee Health Sciences Center (UTHSC), in collaboration with researchers at the University of New Mexico, where researchers led by Colin Johnson, Ph.D., identified zuclopenthixol, nebivolol and amodiaquine as promising treatments for the virus in its early stages, based on Virtual and in vitro antiviral testing that began in the early months of the Covid-19 pandemic.
Researchers have nominated drugs for testing in future clinical trials to improve the immune response to the virus, that amodiaquine is an ancient antimalarial, zuclopenthixol is an antipsychotic, and nebivolol is a blood pressure drug.
The paper states that there is “a strict need for high-quality studies that can provide critical knowledge of Covid-19 disease and reliable treatment proposals.”
According to timesofindia, the researchers said: “With these warnings in mind, we envisioned an algorithmic workflow that includes independent verification in the laboratory, followed by an evaluation of emerging candidates in the context of available clinical pharmacology data with the aim of suggesting suitable candidates for early-stage clinical studies (incubation stages) And symptoms) patients infected with SARS-CoV-2.
“Given the need for improved efficacy and safety, we suggest the use of zuclopenthixol, nebivolol and amodiaquine as potential candidates for clinical trials against early stage SARS-CoV-2 infection,” the researchers wrote.
Comparing the drugs with hydroxychloroquine, an anti-malarial drug that has been frequently studied in clinical trials for use as a treatment for COVID-19, researchers examined 4,000 approved drugs, and found that these three drugs work similarly to hydroxychloroquine, and in some cases more safely.